英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

gasify    音标拼音: [g,æsəfɑɪ]
vt.
vi. (使)气化

(使)气化

gasify
v 1: turn into gas; "The substance gasified" [synonym: {gasify},
{vaporize}, {vaporise}, {aerify}]

Gasify \Gas"i*fy\, v. t. [imp. & p. p. {Gasified}; p. pr. & vb.
n. {Gasifying}.] [Gas -fy.]
To convert into a gas, as by the application of heat, or by
chemical processes.
[1913 Webster]


Gasify \Gas"i*fy\, v. i.
To become gas; to pass from a liquid to a gaseous state.
--Scientific American.
[1913 Webster]


请选择你想看的字典辞典:
单词字典翻译
Gasify查看 Gasify 在百度字典中的解释百度英翻中〔查看〕
Gasify查看 Gasify 在Google字典中的解释Google英翻中〔查看〕
Gasify查看 Gasify 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home | BridgeBio
    BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers
  • BridgeBio Pharma, Inc. (BBIO) Stock Price, News, Quote History . . .
    BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases The company has four programs
  • BridgeBio Files NDA for LGMD2I R9 Oral Therapy - TipRanks
    BridgeBio filed an FDA NDA for BBP-418 in LGMD2I R9 on March 30, 2026, based on positive Phase 3 data If approved, BBP-418 could become the first therapy for LGMD2I R9 and any limb-girdle muscular dystrophy, supported by multiple regulatory designations Looking for the best stocks to buy? Follow the recommendations of top-performing analysts
  • Bridgebio asks FDA to approve potential 1st treatment for LGMD2i
    Bridgebio Pharma asked the FDA to approve BBP-418, an oral therapy that could be the first treatment for LGMD2i
  • BBIO Stock Price | BridgeBio Pharma Inc. Stock Quote (U. S. : Nasdaq . . .
    BridgeBio Pharma, Inc engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases Its pipeline of development programs includes product
  • BridgeBio Submits NDA to FDA for BBP-418 for Individuals . . . - BioSpace
    BridgeBio anticipates a U S launch following FDA approval in late 2026 early 2027 If successful, BBP-418 would be the first and only approved therapy for individuals living with LGMD2I R9, potentially representing the first approval of a therapy for any form of LGMD
  • BridgeBio - LinkedIn
    We exist to bring transformative medicines to people living with genetic conditions Our model pairs advances in genetic science with an entrepreneurial mindset, enabling us to move with urgency
  • California Biotech, Pharma Medical Device Company List
    Abzena is the leading end-to-end bioconjugate complex biologics CDMO + CRO From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need
  • BridgeBio Pharma Inc. - News
    BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
  • List of Biologics Companies in United States
    Adrenas is a subsidiary of BridgeBio, a public company dedicated to finding, developing, and delivering breakthrough medicines for genetic diseases to patients as quickly and safely as possible





中文字典-英文字典  2005-2009